Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
oblimersen + gemtuzumab ozogamicin
- Development stage
- Unknown
- Lead developer
- Genta
- Modality
- MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intravenous
01
Overview
A combination regimen of the antisense oligonucleotide oblimersen and the antibody-drug conjugate gemtuzumab ozogamicin for CD33-positive acute myeloid leukemia. Oblimersen is a phosphorothioate antisense DNA oligonucleotide targeting BCL2 mRNA to reduce BCL-2 protein and enhance apoptosis. Gemtuzumab ozogamicin is a humanized anti-CD33 monoclonal antibody conjugated to the cytotoxic agent calicheamicin; upon binding CD33 on myeloid blasts, it is internalized and releases calicheamicin to induce DNA double-strand breaks and cell death. This combination was studied primarily in relapsed AML in older adults to potentiate GO efficacy by downregulating anti-apoptotic BCL-2.
- Other names
- oblimersen sodium + gemtuzumab ozogamicinG3139 + gemtuzumab ozogamicin
02
Targets
CD33 (Myeloid cell surface antigen CD33)BCL-2 (BCL-2 family)DNA
Beyond the preview
Go deeper on oblimersen + gemtuzumab ozogamicin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on oblimersen + gemtuzumab ozogamicin.